Form 4: Rhythm Pharmaceuticals Executive Joseph Shulman Reports Stock Transactions

Joseph Shulman, Chief Technical Officer of Rhythm Pharmaceuticals, reports the exercise of stock options and subsequent sale of shares on May 9, 2024.

Summary

• On May 9, 2024, Joseph Shulman, the Chief Technical Officer of Rhythm Pharmaceuticals, exercised stock options to acquire 3,984 shares of common stock at a price of $6.80 per share.
• Following the exercise of these options, Shulman sold 3,484 shares at a weighted average price of $38.3776, with individual sales ranging from $37.96 to $38.9599.
• He also sold 500 shares at a weighted average price of $39.102, with individual sales ranging from $39.05 to $40.0499.
• After these transactions, Shulman directly owns 30 shares of Rhythm Pharmaceuticals common stock and 31,875 stock options.
• The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on May 5, 2023.
• Shulman has granted a power of attorney to David Meeker, Jim Flaherty, Hunter Smith, and Christopher German to execute and file necessary forms related to securities transactions.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment about the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the trading activities of company executives. It is standard practice for executives to have pre-arranged trading plans like Rule 10b5-1 to avoid accusations of insider trading.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their executives.
• The transactions are similar to those of executives at comparable pharmaceutical companies who exercise stock options and sell shares for personal financial management.
• The use of a 10b5-1 trading plan is a common method to ensure compliance with insider trading regulations, similar to practices at companies like Amgen or Biogen.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely minimal given the relatively small number of shares involved.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates